CAJ | 학술논문

目的：比较莫西沙星、埃索拉唑和呋喃唑酮三联疗法与经典铋剂四联疗法作为初次治疗方案根除幽门螺杆菌（Hp）感染的疗效与安全性。方法选取126例经胃镜检查证实为 Hp感染上消化道疾病患者，随机分为两组：治疗组（n＝66），给予埃索拉唑、莫西沙星、呋喃唑酮三联10 d治疗；对照组（n＝60），给予经典铋剂四联14 d治疗，疗程结束4周后复查Hp，观察疗效和不良反应。结果治疗组 Hp根除率为89．4％，对照组为88．3％，差异无统计学意义（P＞0．05）；治疗组不良反应发生率（16．7％）明显低于对照组（36．7％），差异有统计学意义（P＜0．05）。结论莫西沙星、埃索拉唑和呋喃唑酮三联 Hp根除率与经典铋剂四联疗法相同，但不良反应少，患者耐受好，安全。
목적：비교막서사성、애색랍서화부남서동삼련요법여경전필제사련요법작위초차치료방안근제유문라간균（Hp）감염적료효여안전성。방법선취126례경위경검사증실위 Hp감염상소화도질병환자，수궤분위량조：치료조（n＝66），급여애색랍서、막서사성、부남서동삼련10 d치료；대조조（n＝60），급여경전필제사련14 d치료，료정결속4주후복사Hp，관찰료효화불량반응。결과치료조 Hp근제솔위89．4％，대조조위88．3％，차이무통계학의의（P＞0．05）；치료조불량반응발생솔（16．7％）명현저우대조조（36．7％），차이유통계학의의（P＜0．05）。결론막서사성、애색랍서화부남서동삼련 Hp근제솔여경전필제사련요법상동，단불량반응소，환자내수호，안전。
Objective To evaluate the efficacy and safety of 10-day moxifloxacin,esomeprazole plus furazolidone triple therapy as first-line treatment to eradicate Helicobacter pylori (Hp)in comparison with the 14-day quadruple therapy containing esomeprazole,amoxicillin, clarithromycin and colloidal bismuth pectin. Methods A total of 1 26 cases of endoscopically confirmed Hp-positive chronic active gastritis or peptic ulcer were randomly assigned to the treatment group to receive esomeprazole,moxifloxacin plus furazolidone triple therapy for 1 0 days;or to the control group to receive esomeprazole, amoxicillin,clarithromycin,and colloidal bismuth pectin quadruple therapy for 14 days.Clinical efficacy and safety were evaluated after 4-week treatment.Results At the end of treatment,the Hp eradication rate was 89.4%in the treatment group, and 88.3% in the control group(P>0.05).The incidence of adverse reactions in the treatment group (16.7%)was significantly lower than that in the control group (36.7%)(P<0.05).Conclusions The 10-day moxifloxacin,esomeprazole plus furazolidone triple therapy is effective and well-tolerated as first-line treatment to eradicate Hp with samilar efficacy and fewer adverse reactions compared to the 14-day bismuth-based quadruple therapy.